Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cleveland BioLabs has reported that the recent primate studies have demonstrated the efficacy of the company's Protectan CBLB502 as a mitigator of hematopoietic damage up to 48 hours post radiation exposure.
Subscribe to our email newsletter
Protectan CBLB502 was administered as a single injection at 48 hours post-exposure to 6.5 Gy doses of ionizing radiation, which results in approximately 75% mortality, if untreated (similar to doses received by Chernobyl firefighters). In the non-human primate model tested, approximately 67% of the Protectan CBLB502-treated animals survived compared to 25% of the control group.
Administration of CBLB502 48 hours post exposure was shown to increase survival, and have a significantly beneficial effect on platelet levels while also reducing the severity of radiation-induced neutropenia.